At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,207 enrolled
Drug / intervention
Candesartan cilexetil +2 moredrug
Likely dose
Candesartan/HCT 32/25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil (CC) 32 mg and Hydrochlorothiazide (HCT) 25 mg Compared With CC 32 mg, HCT 25 mg and Placebo in Hypertensive Adults
In Brief
A Phase 3 clinical trial evaluating Candesartan cilexetil, Hydrochlorothiazide, and 1 other intervention for Hypertension. Completed, enrolled 2,207 participants across 27 sites in 6 countries.
Detailed Summary
The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesBelgium, Latvia, Malta, Romania, Russia, Slovakia
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedFeb 2007
Primary CompletionJan 2008
TodayJul 2026
First PostedFeb 14, 2007
Enrollment StartJan 1, 2007
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 19.4 years ago
Interventions
Candesartan cilexetildrug
32 mg oral tablet
Hydrochlorothiazidedrug
25 mg oral tablet
Candesartan/HCT 32/25 mgdrug